Compare QURE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QURE | MESO |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | Netherlands | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2007 | N/A |
| Metric | QURE | MESO |
|---|---|---|
| Price | $22.82 | $17.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $58.55 | $24.00 |
| AVG Volume (30 Days) | ★ 2.0M | 210.4K |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $15,751,000.00 | ★ $17,198,000.00 |
| Revenue This Year | N/A | $576.59 |
| Revenue Next Year | $142.93 | $41.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 191.39 |
| 52 Week Low | $7.76 | $9.61 |
| 52 Week High | $71.50 | $21.50 |
| Indicator | QURE | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 44.78 | 43.82 |
| Support Level | $21.15 | $17.38 |
| Resistance Level | $28.77 | $18.02 |
| Average True Range (ATR) | 1.60 | 0.67 |
| MACD | 0.23 | -0.27 |
| Stochastic Oscillator | 21.85 | 3.49 |
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.